Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 17 |
| Apr 2026 | 0 | 8 |
| May 2026 | 0 | 9 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 9 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 8 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2017 Filed Jun 2, 2017 21:53 UTC |
Blum Robert IDirector · President & CEO
|
SaleCommon Stock | 100 | $13.40 | $1,340.00 |
DisclosureSEC source: 0001061983-17-000037 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,785 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2017. Read SEC document |
| May 18, 2017 Filed May 22, 2017 17:55 UTC |
COSTA SANTO JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000029 · edgardoc.xml · derivative · entry 1 COSTA SANTO J · CIK 0001013419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC |
GAGE L PATRICKDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000030 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC |
PARSHALL B LYNNEDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000033 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:57 UTC |
WIERENGA WENDALLDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000035 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:57 UTC |
SMITH SANDFORD DDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000034 · edgardoc.xml · derivative · entry 1 SMITH SANDFORD D · CIK 0001243004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC |
Kaye Edward M. MDDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000032 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC |
HENDERSON JOHN TDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000031 · edgardoc.xml · derivative · entry 1 HENDERSON JOHN T · CIK 0001226488 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
WOLFF ANDREW ASVP & CMO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,580 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000020 · edgardoc.xml · derivative · entry 5 WOLFF ANDREW A · CIK 0001238406 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,580 Underlying: Common Stock · 8,580 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
WOLFF ANDREW ASVP & CMO
|
GrantIncentive Stock Option (right to buy) · Derivative | 6,420 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000020 · edgardoc.xml · derivative · entry 4 WOLFF ANDREW A · CIK 0001238406 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,420 Underlying: Common Stock · 6,420 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
WOLFF ANDREW ASVP & CMO
|
GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000020 · edgardoc.xml · nonDerivative · entry 3 WOLFF ANDREW A · CIK 0001238406 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,255 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
WOLFF ANDREW ASVP & CMO
|
Tax withholdingCommon Stock | 4,984 | $10.60 | $52,830.40 |
DisclosureSEC source: 0001061983-17-000020 · edgardoc.xml · nonDerivative · entry 2 WOLFF ANDREW A · CIK 0001238406 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,255 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
WOLFF ANDREW ASVP & CMO
|
GrantCommon Stock | 12,500 | $0.00 | $12.50 |
DisclosureSEC source: 0001061983-17-000020 · edgardoc.xml · nonDerivative · entry 1 WOLFF ANDREW A · CIK 0001238406 · SVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,239 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
BARBARI SHARONEVP, Finance & CFO
|
Tax withholdingCommon Stock | 7,317 | $10.60 | $77,560.20 |
DisclosureSEC source: 0001061983-17-000019 · edgardoc.xml · nonDerivative · entry 2 BARBARI SHARON SURREY · CIK 0001240499 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,323 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:07 UTC |
BARBARI SHARONEVP, Finance & CFO
|
GrantCommon Stock | 18,750 | $0.00 | $18.75 |
DisclosureSEC source: 0001061983-17-000019 · edgardoc.xml · nonDerivative · entry 1 BARBARI SHARON SURREY · CIK 0001240499 · EVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,640 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,537 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · derivative · entry 5 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,537 Underlying: Common Stock · 13,537 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
GrantIncentive Stock Option (right to buy) · Derivative | 6,463 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · derivative · entry 4 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,463 Underlying: Common Stock · 6,463 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 3 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,194 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
Tax withholdingCommon Stock | 5,986 | $10.60 | $63,451.60 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 2 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Morgan Bradley PaulSVP Drug Discovery & Early Dev
|
GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 1 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,180 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Schnieders ElisabethSr. VP, Business Development
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,177 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · derivative · entry 5 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,177 Underlying: Common Stock · 11,177 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Schnieders ElisabethSr. VP, Business Development
|
GrantIncentive Stock Option (right to buy) · Derivative | 8,823 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · derivative · entry 4 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,823 Underlying: Common Stock · 8,823 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Schnieders ElisabethSr. VP, Business Development
|
GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 3 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,919 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Schnieders ElisabethSr. VP, Business Development
|
Tax withholdingCommon Stock | 5,066 | $10.60 | $53,699.60 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 2 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,919 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
Schnieders ElisabethSr. VP, Business Development
|
GrantCommon Stock | 12,500 | $0.00 | $12.50 |
DisclosureSEC source: 0001061983-17-000018 · edgardoc.xml · nonDerivative · entry 1 Schnieders Elisabeth · CIK 0001691076 · Sr. VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,985 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,575 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000016 · edgardoc.xml · derivative · entry 3 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,575 Underlying: Common Stock · 8,575 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 6,425 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000016 · edgardoc.xml · derivative · entry 2 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,425 Underlying: Common Stock · 6,425 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC |
McDowell Caryn GordonGC & Chief Compliance Officer
|
GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000016 · edgardoc.xml · nonDerivative · entry 1 McDowell Caryn Gordon · CIK 0001674232 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,581 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,105 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,105 Underlying: Common Stock · 41,105 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantIncentive Stock Option (right to buy) · Derivative | 8,895 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 Underlying: Common Stock · 8,895 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantCommon Stock | 30,000 | $0.00 | $30.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,404 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Malik Fady IbrahamEVP Research & Development
|
Tax withholdingCommon Stock | 9,631 | $10.60 | $102,088.60 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,404 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Malik Fady IbrahamEVP Research & Development
|
GrantCommon Stock | 25,000 | $0.00 | $25.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,035 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Cragg DavidSVP Human Resources
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,166 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000014 · edgardoc.xml · derivative · entry 5 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,166 Underlying: Common Stock · 14,166 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Cragg DavidSVP Human Resources
|
GrantIncentive Stock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000014 · edgardoc.xml · derivative · entry 4 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Cragg DavidSVP Human Resources
|
GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000014 · edgardoc.xml · nonDerivative · entry 3 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,018 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Cragg DavidSVP Human Resources
|
Tax withholdingCommon Stock | 6,008 | $10.60 | $63,684.80 |
DisclosureSEC source: 0001061983-17-000014 · edgardoc.xml · nonDerivative · entry 2 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,018 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC |
Cragg DavidSVP Human Resources
|
GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000014 · edgardoc.xml · nonDerivative · entry 1 Cragg David · CIK 0001316459 · SVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,026 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
CHARPENTIER BONNIESVP Regulatory & Compliance
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,850 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000013 · edgardoc.xml · derivative · entry 5 CHARPENTIER BONNIE · CIK 0001267267 · SVP Regulatory & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,850 Underlying: Common Stock · 13,850 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
CHARPENTIER BONNIESVP Regulatory & Compliance
|
GrantIncentive Stock Option (right to buy) · Derivative | 6,150 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000013 · edgardoc.xml · derivative · entry 4 CHARPENTIER BONNIE · CIK 0001267267 · SVP Regulatory & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Underlying: Common Stock · 6,150 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
CHARPENTIER BONNIESVP Regulatory & Compliance
|
GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000013 · edgardoc.xml · nonDerivative · entry 3 CHARPENTIER BONNIE · CIK 0001267267 · SVP Regulatory & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,004 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
CHARPENTIER BONNIESVP Regulatory & Compliance
|
Tax withholdingCommon Stock | 5,996 | $10.60 | $63,557.60 |
DisclosureSEC source: 0001061983-17-000013 · edgardoc.xml · nonDerivative · entry 2 CHARPENTIER BONNIE · CIK 0001267267 · SVP Regulatory & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,004 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
CHARPENTIER BONNIESVP Regulatory & Compliance
|
GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000013 · edgardoc.xml · nonDerivative · entry 1 CHARPENTIER BONNIE · CIK 0001267267 · SVP Regulatory & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
Blum Robert IDirector · President & CEO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 194,235 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000012 · edgardoc.xml · derivative · entry 7 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,235 Underlying: Common Stock · 194,235 shares Expires 2027-02-28 F4 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
Blum Robert IDirector · President & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 10,765 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000012 · edgardoc.xml · derivative · entry 6 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 Underlying: Common Stock · 10,765 shares Expires 2027-02-28 F4 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
Blum Robert IDirector · President & CEO
|
Tax withholdingCommon Stock | 17,007 | $10.60 | $180,274.20 |
DisclosureSEC source: 0001061983-17-000012 · edgardoc.xml · nonDerivative · entry 3 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,768 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
Blum Robert IDirector · President & CEO
|
GrantCommon Stock | 45,000 | $0.00 | $45.00 |
DisclosureSEC source: 0001061983-17-000012 · edgardoc.xml · nonDerivative · entry 2 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,775 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:04 UTC |
Blum Robert IDirector · President & CEO
|
GrantCommon Stock | 60,000 | $0.00 | $60.00 |
DisclosureSEC source: 0001061983-17-000012 · edgardoc.xml · nonDerivative · entry 1 Blum Robert I · CIK 0001288859 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,775 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC |
PARSHALL B LYNNEDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $4.96 Strike: $12.40 | $19,999.93 |
DisclosureSEC source: 0001061983-17-000008 · edgardoc.xml · derivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC |
WIERENGA WENDALLDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,032 | $4.96 Strike: $12.40 | $19,999.93 |
DisclosureSEC source: 0001061983-17-000010 · edgardoc.xml · derivative · entry 1 WIERENGA WENDALL · CIK 0001235945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032 Underlying: Common Stock · 4,032 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.